People on the Move
Batu Biologics
Batu Biologics has appointed Alan Lewis as Chairman. The San Diego biotech makes ValloVax, a cancer angiogenesis-targeting immunotherapy which targets what it calls the “Achilles’ heel of cancer”: tumour blood vessels.
He joins the board after a career as CEO of Medistem, Ambit Biosciences, the Juvenile Diabetes Research Foundation, Signal Pharmaceuticals, and Novocell (Viacyte). He also worked for 15 years at Wyeth-Ayerst, where he was VP of Research.
He is currently a board member at BioMarin and severakl private biotechs.
Batu Biologics filed an Investigational Drug Application with the US Food and Drug Administration in December for a Phase I-II trial of ValloVax for non-small cell lung cancer.